Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

Simpson Eric L.; Flohr Carsten; Eichenfield Lawrence F.; Bieber Thomas; Sofen Howard; Taieb Alain; Owen Ryan; Putnam Wendy; Castro Marcela; DeBusk Kendra; Lin Chin-Yu; Voulgari Athina; Yen Karl; Omachi Theodore A.

首页> 外文期刊>Journal of the American Academy of Dermatology >Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

【24h】

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

机译：lebrikizumab（抗IL-13单克隆抗体）在成人中具有中度至严重的特征性皮炎的疗效和安全性因局部皮质类固醇不足：随机，安慰剂控制的第二阶段试验（高音）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Interleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging pathogenic mediator in atopic dermatitis (AD).

机译：背景：白细胞介素（IL）-13在2型炎症中发挥关键作用，是特应性皮炎（AD）的新出生致病介质。

著录项

来源
《Journal of the American Academy of Dermatology》 |2018年第5期|共20页
作者
Simpson Eric L.; Flohr Carsten; Eichenfield Lawrence F.; Bieber Thomas; Sofen Howard; Taieb Alain; Owen Ryan; Putnam Wendy; Castro Marcela; DeBusk Kendra; Lin Chin-Yu; Voulgari Athina; Yen Karl; Omachi Theodore A.;
展开▼
作者单位

Oregon Hlth &

Sci Univ Sch Med Dept Dermatol Portland OR 97201 USA;

Kings Coll London St Johns Inst Dermatol London England;

Univ Calif San Diego Dept Dermatol La Jolla CA 92093 USA;

Univ Med Ctr Dept Dermatol &

Allergy Bonn Germany;

Univ Calif Los Angeles Sch Med Los Angeles CA 90024 USA;

Bordeaux Hosp Univ Ctr Dept Dermatol &

Pediat Dermatol Bordeaux France;

Genentech Inc 1 DNA Way MS 452a San Francisco CA 94080 USA;

Genentech Inc 1 DNA Way MS 452a San Francisco CA 94080 USA;

Genentech Inc 1 DNA Way MS 452a San Francisco CA 94080 USA;

Genentech Inc 1 DNA Way MS 452a San Francisco CA 94080 USA;

Genentech Inc 1 DNA Way MS 452a San Francisco CA 94080 USA;

Roche Prod Ltd Global Prod Dev Clin Sci Welwyn Garden City Herts England;

Roche Grenzacherstr Basel Switzerland;

Genentech Inc 1 DNA Way MS 452a San Francisco CA 94080 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病学与性病学;
关键词
anti-IL-13; atopic dermatitis; EASI; lebrikizumab; pruritus; topical corticosteroids;

机译：抗IL-13;特应性皮炎;EASI;lebrikizumab;痒;局部皮质类固醇;

相似文献

外文文献
中文文献

1. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE) [J] . Simpson Eric L., Flohr Carsten, Eichenfield Lawrence F., Journal of the American Academy of Dermatology . 2018,第5期

机译：lebrikizumab（抗IL-13单克隆抗体）在成人中具有中度至严重的特征性皮炎的疗效和安全性因局部皮质类固醇不足：随机，安慰剂控制的第二阶段试验（高音）
2. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial [J] . Thaci Diamant, Simpson Eric L., Beck Lisa A., The Lancet . 2016,第10013期

机译：局部治疗不足以控制中度至重度特应性皮炎的成人dupilumab的疗效和安全性：一项随机，安慰剂对照，剂量范围为2b的试验
3. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial [J] . Guttman-Yassky Emma, Brunner Patrick M., Neumann Avidan U., Journal of the American Academy of Dermatology . 2018,第5期

机译：Fezakinumab（IL-22单克隆抗体）在成人中具有中度至重度的特征性皮炎的疗效和安全性因常规治疗不足：随机，双盲，相2A试验
4. A double-blind, randomized phase II trial of thesafety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults [C] . Shelly A. McNeil, Scott A. Halperin, Joanne M. Langley, Lancefield International Symposium on Streptococci and Streptococcal Diseases . 2006

机译：一种双盲，随机期II试验，对健康成人的26岁的26岁群体的疫苗疫苗
5. Topical Probiotics in the Treatment of Atopic Dermatitis: A Randomized Controlled Trial [D] . Chen, Jessica. 2018

机译：局部益生菌治疗特应性皮炎：随机对照试验
6. Extended report: Efficacy and safety of tabalumab an anti-BAFF monoclonal antibody in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised double-blind placebo-controlled phase 3 study [O] . Michael Schiff, Bernard Combe, Thomas Dörner, 2015

机译：扩展报告：抗BAFF单克隆抗体塔巴木单抗对中度至重度类风湿性关节炎和对TNF抑制剂反应不足的患者的疗效和安全性：一项随机双盲安慰剂对照3期研究的结果
7. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids:A randomized, placebo-controlled phase II trial (TREBLE) [O] . Simpson, Eric L., Flohr, Carsten, Eichenfield, Lawrence F., 2019

机译：Lebrikizumab（抗IL-13单克隆抗体）在局部至局部皮质类固醇激素控制不充分的中度至重度特应性皮炎成人中的疗效和安全性：一项随机，安慰剂对照的II期临床试验（TREBLE）

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

摘要

著录项

相似文献

相关主题

期刊订阅